Last updated Nov 9, 2026
A 6-month-old of Ashkenazi Jewish ancestry has developmental regression, exaggerated startle response, and cherry-red spot on fundoscopy. Hexosaminidase A is deficient.
AR; HEXA (the alpha subunit of beta-hexosaminidase A, the lysosomal enzyme that degrades GM2 ganglioside). Biallelic loss-of-function variants; residual activity sets the age of onset.
- Common in Ashkenazi Jewish, French Canadian, Cajun populations
- Tay-Sachs is the most common of the three GM2 gangliosidoses, and the Sandhoff disease and GM2 activator deficiency page compares all three
Beta-hexosaminidase A is a heterodimer of one alpha chain (HEXA) and one beta chain (HEXB), and it is the only hexosaminidase that can degrade GM2 ganglioside. GM2 is normally present in neurons only in small amounts, but neurons make complex gangliosides faster than any other cell, so when the alpha chain fails GM2 builds up there. The neurons are impaired and then lost: regression from 3 to 6 months, exaggerated startle, seizures, and the cherry-red spot, from storage in retinal ganglion cells around the fovea. Hexosaminidase B (two beta chains) is spared, which is why its activity is normal while hexosaminidase A, and the total, are low.
Residual activity runs inversely with severity:
- Two null alleles: acute infantile disease. The common Ashkenazi variants c.1274_1277dupTATC and c.1421+1G>C, and the French Canadian 7.6-kb deletion, are null.
- One null and one missense allele: subacute juvenile disease.
- Two missense alleles: late-onset disease; p.Gly269Ser is the most common.
Enzyme testing can mislead both ways. Pseudodeficiency alleles (p.Arg247Trp, p.Arg249Trp) fail only on the synthetic substrate and give false positives, and the B1 allele (p.Arg178His) handles the synthetic but not the natural substrate and gives false negatives, so DNA testing confirms.
Part of lysosomal sphingolipid degradation.
Lysosomal ganglioside degradation, the GM2 step.
GM2 ganglioside with the GM2 activator protein → beta-hexosaminidase A (the block; alpha subunit) → GM3 ganglioside → lactosylceramide → on to ceramide
- Accumulates: GM2 ganglioside in neurons; the lab measures low hexosaminidase A activity and a low hexosaminidase A share of the total, with normal hexosaminidase B.
- Missing: GM2 clearance; the disease comes from neuronal storage and loss.
- Workbook: 7.E. Tay-Sachs disease
- GM2 ganglioside accumulation
- Normal at birth, regression begins 3-6 months
- Cherry-red spot on macula
- Exaggerated startle response
- Progressive neurodegeneration, blindness, seizures
- Macrocephaly
- Infantile form: death usually by age 2 to 3 years, extended to 5 to 7 years with gastrostomy feeding and airway care
Carrier Screening: Enzyme assay or DNA testing for at-risk populations
- Deficient hexosaminidase A enzyme activity in serum or leukocytes, with normal Hex B activity (total hexosaminidase is reduced, and the Hex A share of it is low)
- HEXA molecular testing confirms the diagnosis and resolves pseudodeficiency alleles that lower enzyme activity without causing disease
- Cherry-red macula on fundoscopy supports the clinical picture
- No disease-modifying therapy; supportive and palliative care
- Anticonvulsants for seizures, nutritional support for dysphagia, secretion management
- Genetic counseling and carrier screening for at-risk populations; prenatal/preimplantation testing options
- GoldMan: GM2 ganglioside accumulates in the Gray Matter
- Startle response (exaggerated)
- Ashkenazi Jewish ancestry
- Cherry-red spot on the macula
- Hexosaminidase A
- Seizures and neurodegeneration
tAy sAchs = hexA: Tay-Sachs is caused by deficiency of hexosaminidase A. Compare with Sand-hoff = hexB ("get the Sand off at the Beach").
Tay-Sachs has a Typical Spleen: no hepatosplenomegaly (vs. Niemann-Pick, which has a Massive sPleen). Both have a cherry-red spot on the macula.